Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

S Jeske, ST Tagawa, O Olowokure, J Selzer… - … Oncology: Seminars and …, 2011 - Elsevier
OBJECTIVES: Docetaxel is considered first-line chemotherapy for patients with metastatic
castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated …
被引用次数：20 相关文章

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

S Jeske, ST Tagawa, O Olowokure, J Selzer… - Urologic …, 2010 - europepmc.org
Objectives Docetaxel is considered first-line chemotherapy for patients with metastatic
castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated …

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

S Jeske, ST Tagawa, O Olowokure… - Urologic …, 2011 - pubmed.ncbi.nlm.nih.gov
Objectives Docetaxel is considered first-line chemotherapy for patients with metastatic
castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated …

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

S Jeske, ST Tagawa, O Olowokure, J Selzer… - … Oncology: Seminars and …, 2011 - infona.pl
Docetaxel is considered first-line chemotherapy for patients with metastatic castrate resistant
prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated activity in CRPC but …

[引用][C] Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

S JESKE, ST TAGAWA, O OLOWOKURE… - Urologic …, 2011 - pascal-francis.inist.fr
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant
prostate cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

[引用][C] Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

S JESKE, ST TAGAWA, O OLOWOKURE, J SELZER… - Urologic oncology, 2011 - Elsevier